News Updates
More Articles
- Benefits of Integrating Patient Engagement with Diversity, Equity, and Inclusion in New Medical Product Development: A Call for Action
- Drug Shortages in the Global South: A Proposed Parallel Tech and Reg Transfer Framework
- Fair Pay for Patient Engagement: Navigating the Evolving Landscape of Remuneration
- Industry’s Window to Express Interest in Africa Continental Product Evaluation Pilot Closes End of February 2024
- Accelerating Adoption of eLabeling in Singapore: One Company’s Journey
Linking Regulations with Diversity, Inclusion and New Opportunities in Decentralized Clinical Trials
In the US, the federal government has implemented a series of regulatory actions to overcome D&I deficiencies. These efforts should continue to address multiple dimensions related to the implementation of DCTs (decentralized clinical trials) enabled by DHTs (digital health technologies) and the accessibility by diverse populations.
×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!